CHMP disregards PRAC call to suspend Servier's Protelos in EU
This article was originally published in Scrip
Executive Summary
The European Medicines Agency says that Servier's osteoporosis treatment Protelos/Osseor (strontium ranelate) should remain on the market with additional restrictions, even though its Pharmacovigilance Risk Assessment Committee (PRAC) recommended in January that the product should be suspended.